This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down to learn more

Proven Efficacy

11.2 cm annualised height velocity and 1.25 change in height SDS - both comparable to daily GH1,a,b
Established Safety

Safety and tolerability profile comparable to daily GH1
Fewer Injections

Provides 313 injection-free days compared to current daily treatments4
Proven Efficacy

11.2 cm annualised height velocity and 1.25 change in height SDS - both comparable to daily GH1,a,b
Established Safety

Safety and tolerability profile comparable to daily GH1
Fewer Injections

Provides 313 injection-free days compared to current daily treatments4

Patient-Preferred Device

Easy, well-known, and ready-to-use prefilled device1,2,4
Minimal Pain

Only 1.5% of patients reported injection site pain - comparable to daily GH4
Portable

Stable at room temperature for up to 72 hours (<30°C)1
Patient-Preferred Device

Easy, well-known, and ready-to-use prefilled device1,2,4
Minimal Pain

Only 1.5% of patients reported injection site pain - comparable to daily GH4
Portable

Stable at room temperature for up to 72 hours (<30°C)1

a Estimated treatment difference (ETD) [95% CI] = 0.5 [-1.1; 0.2]1
b Estimated treatment difference (ETD) [95% CI] = 0.05 [-0.18; 0.08]1
c 0.025 mg is the minimum dosing increment for the 5 mg/1.5 ml pen, 0.05 mg is the minimum dosing increment for the 10 mg/1.5 ml pen and 0.1 mg is the minimum dosing increment for the 15 mg/1.5 ml pen.1

Once-weekly Sogroya® is a novel long-acting, recombinant human growth hormone to which an albumin-binding side chain has been attached.6 The side chain consists of a fatty acid moiety which connects Sogroya® to endogenous albumin.6 The reversible association to endogenous albumin extends the in-vivo half-life of Sogroya® and reduces clearance in the kidneys, thereby prolonging the duration of action.7

1.

Sogroya® Summary of Product Characteristics. 2022:1-92.

2.

Norditropin® FlexPro® Summary of Product Characteristics. 2021:1-65.

3.

Rohrer. T.R., Horikawa, R., & Kappelgaard, A. M. (2017). Growth hormone delivery devices: current features and potential for enhanced treatment adherence. Expert Opin Drug Deliv. 2017;14(11): 1253-1264.

4.

Miller BS JC Rasmussen MH, et al. Weekly Somapacitan is Effective and Well Tolerated In children With GH Deficiency: The Randomised Phase 3 REAL4 Trial. J Clin Endocrinol Metab. 022:00(0):1-11.

5.

Levemir® Prescribing Information, 2022.

6.

Rasmussen MH, Olsen MW, Alifrangis L, Klim S, Suntum M. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile. J Clin Endocrinol Metab. 2014 Oct;99(10):E1819-29. doi: 10.1210/jc.2014-1702. Epub 2014 Jul 11. PMID: 25013997.

7.

Petersen M, Gandhi PS, Buchardt J, Alanentalo T, Fels JJ, Johansen NL, Heiding-Kvist P, Vad K, Thygesen P. Tissue Distribution and Receptor Activation by Somapacitan, a Long Acting Growth Hormone Derivative. Int J Mol Sci. 2020 Feb 11;21(4):1181. doi: 10.3390/ijms21041181. PMID: 32053994; PMCID: PMC7072805.